Wow, just wow!
Across the Puget Sound, Seattle
Yesterday we highlighted an emerging CAR-T cell therapy company in China with a different approach to hematologic malignancies.
We now turn our attention Stateside to focus on another biotech company who are parlaying solid academic research into more robust CAR-T cell therapies for solid tumours.
For too long researchers have struggled with a number of challenges in this setting from too many toxicities, lack of specificity, to too little activity or persistence.
It’s about time we changed this negative perception.
Here we look at some impressive work presented by a go-getting researcher and his lab who have some cool ideas and are quietly taking on the obstacles by storm. He also happens to be a co-founder of an emerging biotech who benefit from their creativity…
To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
